Last reviewed · How we verify
NCT05043688
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
Phase 3 trial testing Camrelizumab in Resectable Esophageal Squamous Cell Carcinoma in 426 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Zhigang Li |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 426 |
| Start date | 1 September 2021 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2030 |
| Sites | 5 locations across China |
Drugs / interventions tested
- Camrelizumab — full drug profile →
- radiotherapy — full drug profile →
Conditions studied
- Resectable Esophageal Squamous Cell Carcinoma — all drugs for Resectable Esophageal Squamous Cell Carcinoma →
Sponsor
Zhigang Li — full company profile →
Who can join
Adults 18 to 75, any sex, with Resectable Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to explore the effectiveness and safety of neoadjuvant immune combined chemotherapy or radiochemotherapy compared with traditional neoadjuvant radiochemotherapy in patients with locally advanced Esophageal Squamous Cell Carcinoma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
Liu J, Yang Y, Liu Z, Fu X, et al · · 2022 · cited 217× · PMID 35338088 · DOI 10.1136/jitc-2021-004291 -
Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
Li Q, Liu T, Ding Z. · · 2022 · cited 43× · PMID 36569908 · DOI 10.3389/fimmu.2022.1051841 -
Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study).
Yang Y, Zhu L, Cheng Y, Liu Z, et al · · 2022 · cited 31× · PMID 35524205 · DOI 10.1186/s12885-022-09573-6 -
Immune-based combination therapy for esophageal cancer.
Wang H, Xu Y, Zuo F, Liu J, et al · · 2022 · cited 24× · PMID 36591219 · DOI 10.3389/fimmu.2022.1020290 -
Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions.
Jiang M, Hu Y, Lin G, Chen C, et al · · 2023 · cited 18× · PMID 37325652 · DOI 10.3389/fimmu.2023.1177085 -
Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
Gervaso L, Ciardiello D, Oliveira RA, Borghesani M, et al · · 2024 · cited 12× · PMID 38782539 · DOI 10.1136/jitc-2023-008027 -
Targeting esophageal carcinoma: molecular mechanisms and clinical studies.
Wang W, Ye L, Li H, Mao W, et al · · 2024 · cited 7× · PMID 39415846 · DOI 10.1002/mco2.782 -
Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research.
Kumar R, Kim J, Deek MP, Eskander MF, et al · · 2023 · cited 7× · PMID 37504333 · DOI 10.3390/curroncol30070473
Verify or expand the search:
- PubMed search for NCT05043688
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Camrelizumab
Trials testing the same drug.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
- NCT07466901 — A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Rad · NA · not yet recruiting
- NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
- NCT07266350 — A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for th · not yet recruiting
Other recruiting trials for Resectable Esophageal Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT07457528 — Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC · Phase 2 · recruiting
Other Zhigang Li trials
Trials by the same sponsor.
- NCT07524374 — SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05043688 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhigang Li
- Last refreshed: 17 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05043688.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing